BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19475643)

  • 1. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.
    You B; Girard P; Paparel P; Freyer G; Ruffion A; Charrié A; Hénin E; Tod M; Perrin P
    Prostate; 2009 Sep; 69(12):1325-33. PubMed ID: 19475643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
    Patel DA; Presti JC; McNeal JE; Gill H; Brooks JD; King CR
    J Clin Oncol; 2005 Sep; 23(25):6157-62. PubMed ID: 16135482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Inman BA; Harel F; Audet JF; Meyer F; Douville P; Fradet Y; Lacombe L
    Eur Urol; 2005 May; 47(5):695-702. PubMed ID: 15826765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens.
    May M; Kaufmann O; Hammermann F; Loy V; Siegsmund M
    BJU Int; 2007 Mar; 99(3):539-44. PubMed ID: 17155973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S; Lepor H; Yaffee R; Taneja SS
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
    Müntener M; Epstein JI; Hernandez DJ; Gonzalgo ML; Mangold L; Humphreys E; Walsh PC; Partin AW; Nielsen ME
    Eur Urol; 2008 Apr; 53(4):767-75; discussion 775-6. PubMed ID: 18060681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of persistently detectable PSA after radical prostatectomy.
    Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
    Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
    Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
    Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.